PT1131316E - Processo quimico e formulacao farmaceutica melhorados - Google Patents

Processo quimico e formulacao farmaceutica melhorados

Info

Publication number
PT1131316E
PT1131316E PT99962610T PT99962610T PT1131316E PT 1131316 E PT1131316 E PT 1131316E PT 99962610 T PT99962610 T PT 99962610T PT 99962610 T PT99962610 T PT 99962610T PT 1131316 E PT1131316 E PT 1131316E
Authority
PT
Portugal
Prior art keywords
manufacturing
substituted sulphinyl
formula
compound
adjusted
Prior art date
Application number
PT99962610T
Other languages
English (en)
Inventor
Magnus Erickson
Anders Gustavsson
Lars Josefsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1131316(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9803953A external-priority patent/SE9803953D0/xx
Priority claimed from SE9803952A external-priority patent/SE9803952D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1131316E publication Critical patent/PT1131316E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PT99962610T 1998-11-18 1999-11-15 Processo quimico e formulacao farmaceutica melhorados PT1131316E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803953A SE9803953D0 (sv) 1998-11-18 1998-11-18 Improved chemical process
SE9803952A SE9803952D0 (sv) 1998-11-18 1998-11-18 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
PT1131316E true PT1131316E (pt) 2004-10-29

Family

ID=26663439

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99962610T PT1131316E (pt) 1998-11-18 1999-11-15 Processo quimico e formulacao farmaceutica melhorados

Country Status (18)

Country Link
US (1) US6403616B1 (pt)
EP (1) EP1131316B1 (pt)
JP (1) JP4610086B2 (pt)
KR (1) KR100619200B1 (pt)
CN (1) CN100503598C (pt)
AT (1) ATE271556T1 (pt)
AU (1) AU770633B2 (pt)
BR (1) BR9915421A (pt)
CA (1) CA2347981C (pt)
DE (1) DE69918854T2 (pt)
DK (1) DK1131316T3 (pt)
ES (1) ES2222754T3 (pt)
HK (1) HK1038920B (pt)
IL (2) IL142629A0 (pt)
NO (1) NO321275B1 (pt)
NZ (1) NZ511169A (pt)
PT (1) PT1131316E (pt)
WO (1) WO2000028975A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
HUE037704T2 (hu) 2011-11-10 2018-09-28 Rotam Agrochem Int Co Ltd Herbicid kompozíció, és eljárás annak alkalmazására
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE69127275T2 (de) 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
AUPN846496A0 (en) * 1996-03-05 1996-03-28 Research Laboratories Of Australia Pty Ltd Electronic printing for display technology
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
EP0839323B1 (en) * 1996-05-17 2004-08-25 Formfactor, Inc. Microelectronic spring contact elements
CN1128997C (zh) * 2001-01-04 2003-11-26 中国科学院南京土壤研究所 一种吸力平板的制作方法

Also Published As

Publication number Publication date
US6403616B1 (en) 2002-06-11
WO2000028975A2 (en) 2000-05-25
CN1326455A (zh) 2001-12-12
EP1131316B1 (en) 2004-07-21
WO2000028975A3 (en) 2000-08-10
JP4610086B2 (ja) 2011-01-12
DE69918854D1 (de) 2004-08-26
CA2347981C (en) 2010-05-04
HK1038920B (zh) 2005-03-11
JP2002529497A (ja) 2002-09-10
EP1131316A2 (en) 2001-09-12
ES2222754T3 (es) 2005-02-01
AU770633B2 (en) 2004-02-26
NO321275B1 (no) 2006-04-10
DE69918854T2 (de) 2005-07-21
BR9915421A (pt) 2001-08-07
AU1901700A (en) 2000-06-05
KR100619200B1 (ko) 2006-09-05
IL142629A (en) 2007-12-03
CN100503598C (zh) 2009-06-24
ATE271556T1 (de) 2004-08-15
KR20010089474A (ko) 2001-10-06
NO20012427D0 (no) 2001-05-16
CA2347981A1 (en) 2000-05-25
NO20012427L (no) 2001-07-09
DK1131316T3 (da) 2004-09-27
IL142629A0 (en) 2002-03-10
NZ511169A (en) 2003-06-30
HK1038920A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
PT1131316E (pt) Processo quimico e formulacao farmaceutica melhorados
DE60036924D1 (de) 5-ht1f agonisten
JP2002529497A5 (pt)
MY115018A (en) New process for the preparation of ropivacaine hydrochloride monohydrate
TR200200745T2 (tr) Fenilasetik asit türevleri için proses.
AR029002A1 (es) Proceso para preparar compuestos de acidos quinolin-2-carboxilicos y de sus sales farmaceuticamente aceptables
IT1313617B1 (it) Processo per la preparazione di derivati degli acidi biliari.
MXPA04005210A (es) Procedimiento para la preparacion de composiciones que tienen una cantidad incrementada de sales farmaceuticamente activas de rotameros.
ES2441970T3 (es) Método para producir lansoprazol
GB1436502A (en) Amide derivatives of 3-benzoylphenyl-alkanoic acids
TH64461A (th) กระบวนการสำหรับการเตรียม 2-[5-(4-ฟลูออโรฟีนิล)-3-ไพริดิลเมทธิลอะมิโนเมทธิล]โครแมน
DK1148140T3 (da) Fremgangsmåde til fremstilling af D-asparaginderivater
CN103172544A (zh) 一种精氨酸布洛芬结晶物的制备方法
GB1156854A (en) Lactones of Optically Active Heterocyclic Amino Acids and Process for the Preparation thereof
TH3125A (th) สารอนุพันธ์ของควิโนลีนคาร์บอกซิลิคแอซิด และกรรมวิธีในการเตรียมสารนั้น
GB1188959A (en) 2-Substituted Pyridines as Anthelmintic Agents
Henriksen A dimer of 3-amino-2-cyano-3-hydroxydithioacrylic acid
TH13949EX (th) วิธีการเตรียมยารับประทานซึ่งถูกเคลือบเพื่อให้ละลายในลำไส้ซึ่งมีสารประกอบที่ไม่เสถียรในกรด
TH34905A (th) กระบวนการเตรียมตัวต่อต้าน nmda
TH85798A (th) อนุพันธ์ของอะเซทิลีน
CZ20003867A3 (cs) Amidy a jejich použití
TH20763B (th) สูตรผสมเอเควียสริสเพอริโดน
NO20015465L (no) Spraytörking av trombin-inhibitorer
TH42575A3 (th) กระบวนการในการผลิตแบบใหม่
GB732820A (en) Process for preparing 1,4-diphenyl-3,5-diketopyrazolidine and its derivatives